2.960USD-2.63%Mkt Cap: 132.73M USDP/E: —Last update: 2026-06-01
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap132.73M USD
Enterprise Value113.05M USD
Revenue (TTM)8.00K USD
Gross Profit8.00K USD
Net Income (TTM)-32.15M USD
Revenue/Share0.0000 USD
Last Price2.960 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees25
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.00
PEG—
EV/EBITDA-3.29
EV/Revenue14131.16
P/S17095.41
P/B5.91
EPS (TTM)-0.85
EPS (Forward)-0.76
52W Range
2.29011% of range8.535
52W High8.535 USD
52W Low2.290 USD
Profitability
Gross Margin100.00%
Oper. Margin-432112.50%
EBITDA Margin0.00%
Profit Margin-401812.50%
ROE-278.46%
ROA-168.94%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-25.27M USD
CapEx (TTM)1.10M USD
FCF Margin-194795.31%
FCF Yield-11.74%
Net Debt-23.71M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity0.15
Current Ratio3.68
Quick Ratio3.60
Book Value/Sh0.5160 USD
Cash/Share0.5840 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)17.50 USD
Target Range10.00 USD – 31.00 USD
# Analysts6
Ownership
Shares Out.44.84M
Float36.53M
Insiders10.74%
Institutions30.68%
Short Interest
Short Ratio17.0d
Short % Float6.80%
Short % Out.6.60%
Shares Short2.96M
Short (prev mo.)3.02M
Technical
SMA 502.711 (+9.2%)
SMA 2003.767 (-21.4%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)153.44K
Avg Vol (10d)151.83K
Technical Indicators
RSI (14)57.2
MACD0.0854
MACD Signal0.0803
MACD Hist.+0.0052
BB Upper3.179 USD
BB Middle2.939 USD
BB Lower2.699 USD
BB Width16.37%
ATR (14)0.1831 USD
Vol Ratio (20d)0.49x